key: cord-0773127-npht9dk0
authors: Su, Wen-Lin; Lu, Kuo-Cheng; Chan, Chih-Yu; Chao, You-Chen
title: COVID-19 and the Lungs: A Review
date: 2021-10-02
journal: J Infect Public Health
DOI: 10.1016/j.jiph.2021.09.024
sha: 52b528b3f26d930c7833d6e4c71aedbd0bedbce3
doc_id: 773127
cord_uid: npht9dk0

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) attacks pulmonary alveolar cells via angiotensin-converting enzyme 2 (ACE2) receptors and causes pulmonary infections that result in coronavirus disease (COVID-19), inducing immune responses that can result in severe pneumonia. We reviewed the clinical experiences of lung diseases during the COVID-19 pandemic to offer insights into the adaptations made by experts in the diagnosis and treatment of these comorbidities. Various lung comorbidities increase the severity of COVID-19 and associated mortality by amplifying ACE2 expression. Additionally, the COVID-19 pandemic has changed the use of routine diagnostic pulmonary imaging methods, making chest sonography scoring the most convenient, as it can be conducted bedside. Treatment protocols for SARS-CoV-2 infection and the underlying lung diseases are also affected owing to potential interactions. The optimal diagnostic methods and treatment protocols for lung diseases have been adapted worldwide to increase survival rates and attenuate acute lung injuries during the COVID-19 pandemic.

The coronavirus disease outbreak occurred by the end of 2019 [1] , and thereafter, the COVID-19 burden has significantly increased worldwide.

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection was declared a pandemic with clinical symptoms such as fever, cough, dyspnea, pneumonia, and even acute respiratory distress syndrome (ARDS) [1] . The initial analysis of disease severity revealed that 31.7% of patients with COVID-19 needed intensive care unit (ICU) care, 29% had ARDS, 5% needed extracorporeal membrane oxygenation, and 15% had died [1] . As of February 29, 2020, the overall mortality rate in Wuhan, the epicenter of infection, was less than 1.4%.

The median mortality rate of patients with COVID-19 in each country was calculated to be 1.5%-2% by Johns Hopkins university [2] . Recently, has become the leading cause of death in the U.S., especially among elderly individuals [3] .

SARS-CoV-2 infects the nasopharynx and lungs, resulting in various symptoms of varying severity. The infected patients range from asymptomatic individuals to those with upper respiratory tract infections, smell and taste abnormalities, diarrhea, pneumonia, and even ARDS. Angiotensin-converting enzyme 2 (ACE2) J o u r n a l P r e -p r o o f receptors [4] , to which the coronavirus binds, are found on type 2 alveolar, ciliated, and goblet cells in the airways [5] . Hypoxia is frequently experienced by patients with COVID-19, especially those with comorbidities that affect the lungs.

Furthermore, SARS-CoV-2 infection can induce cytokine storms that damage the lungs and result in ARDS and pulmonary fibrosis [6] . In contrast, SARS-CoV-2 may be able to escape the innate immune response [6] . COVID-19 may disturb the immune function; worsen underlying pulmonary diseases, such as chronic obstructive pulmonary disease (COPD) and cancer, and transplantation outcome;

and cause additive mortality. Furthermore, COVID-19 may influence the diagnosis and treatment of pulmonary diseases, which need imaging techniques, invasive procedures, and chemoimmunotherapy. Information regarding the risks and benefits of clinical diagnostic methods and treatment protocols is limited. Therefore, we reviewed the clinical diagnostic methods and treatment protocols of pulmonary diseases that were affected by the COVID-19 pandemic during 2020.

For this purpose, we searched PUBMED for relevant articles using the keywords COVID-19, ACE2, pathophysiology, COPD, cancer, transplantation, image, and histopathology. One hundred and seven review and research articles were obtained for pathophysiology with the keywords COVID-19, ACE2, pathophysiology, and histopathology. To obtain review articles, case reports, clinical study reports, and J o u r n a l P r e -p r o o f guidelines regarding COVID-19 and pulmonary diseases, we searched the database with COVID-19 and COPD, or lung cancer, or lung transplantation as keywords. In total 158, 299, and 175 articles were obtained for COVID-19 and COPD, lung cancer, and lung transplantation, respectively. To determine the effect of pulmonary imaging on COVID-19, the keywords images (sonography, tomography) and COVID-19 were used to search for review articles; 108 and 322 articles were retrieved, respectively. Additionally, this review offers insights into the pathogenesis of COVID-19 and the adaptations made by experts to pulmonary disease diagnosis and treatment.

Initially, the spike protein of SARS-CoV-2 binds to the ACE2 receptor on the surface of lung epithelial cells, type 2 alveolar cells, and endothelial cells [4] ( Fig. 1) . A human type 2 transmembrane serine protease (TMPRSS2) prime S glycoprotein facilitates virus entry into these host cells. The virus enters the cell cytoplasm and releases its RNA for replication using the host cell machinery, which results in multiplication of the virus that spreads to other host cells. In the human immune system, the cells that recognize the viral antigens become J o u r n a l P r e -p r o o f antigen-presenting cells that process the viral antigens to attract natural killer (NK) cells and CD8 + cytotoxic T cells. Therefore, both innate and adaptive immune systems are activated, and pro-inflammatory cytokines and chemokines are produced.

The traditional innate immune system response to virus infection involves macrophages, monocytes, dendritic cells, and neutrophils (Fig. 2) . These immune cells express a variety of pattern recognition receptors (PRRs) that can detect virus-induced pathogen-associated molecular patterns (PAMPs). The endosomal

PRRs are toll-like receptors (TLRs) 3, 7, and 8, which recognize extracellular PAMPs, such as viral RNA [7] . The other PRRs are cytoplasmic RNA sensors, such as retinoic acid-inducible gene I (RIG-I) and melanoma differentiationassociated protein 5 (MDA5). The TLRs trigger the expression of proinflammatory cytokine-inducing transcription factors, such as nuclear factorkappa B (NF-κB) and RIG-1/MDA5, and activate interferon response factor 3 (IRF3), or activation protein 1. IRF3 triggers the increased expression of type I interferon (T1IFN), which is a typical antiviral cytokine, whereas the NF-κB pathway triggers the expression of innate pro-inflammatory cytokines NF-κB can also be triggered by the renin-angiotensin-aldosterone system (RAAS). Initially, SARS-CoV-2 downregulates ACE2, which is important for the conversion of angiotensin (Ang) II to angiotensin (1-7) [9] (Fig. 3) . Thus, Ang II accumulates and binds to the angiotensin type 1 receptor (AT1R) on the immune cell membrane; this process activates the NF-κB pathway. This, in turn, induces IL-6, TNF-α, IL-1β, and IL-10 production. Ang II activates AT1R and regulates mitogen-activated protein kinases (MAPK) (ERK1/2, JNK, p38MPK) to release the cytokines IL-1, IL-10, IL-12, and TNF-α.

The other pathogen recognition sensors are in the cytosol, such as nucleotidebinding domain leucine-rich repeat (NLR) proteins. NLRs detect endogenous danger-associated molecular patterns (DAMPs) within cells, and then trigger inflammasomes. Inflammasomes convert pro-caspase-1 to active caspase-1.

Caspase-1 converts pro-IL-1β to active IL-1β. Additionally, NK cells are considered a part of the innate immune system as they destroy virus-infected cells.

The adaptive immune cells recognize and protect against invading viruses after the activation of innate immunity; these cells induce CD4 + T lymphocyte-derived J o u r n a l P r e -p r o o f cytokine expression, CD8 + T lymphocyte-mediated cytotoxicity, and B cell antibody production (Fig. 2) . SARS-CoV-2 may stimulate the CD4 + T lymphocytes, which differentiate into Th1 cells. IL-6 and granulocyte macrophage colony-stimulating factor (GM-CSF) are then released from these Th1 cells. Thereafter, the CD14 + CD16 + monocytes in the blood circulate into the lungs. These specific monocytes may become alveolar macrophages. In adaptive immunity, CD8 + T cells (cytolytic) secrete granulysin, which is mediated by perforin. This process triggers the apoptosis of cytotoxic T and antigen-presenting cells. Finally, the over-activation of antigenic activity is prevented.

Eicosanoids are pro-inflammatory bioactive lipid mediators, such as prostaglandins and leukotrienes. SARS-CoV-2 may activate inflammasomes and induce eicosanoid storms (Fig. 2) . During the eicosanoid storm inflammation, the levels of specialized pro-resolving mediators (SPMs) are reduced. SPMs induce the macrophage-mediated clearance of debris and counter pro-inflammatory cytokine production, which reduces inflammation [10] . They alleviate inflammation in influenza. Arachidonic acid-derived epoxyeicosatrienoic acids (EETs) also reduce and alleviate inflammation. EETs may induce the production of mediators in the anti-inflammatory processes. Treatment with SPMs or EETs J o u r n a l P r e -p r o o f may stimulate macrophage phagocytosis, decrease pro-inflammatory cytokine levels, diminish leukocytosis, and attenuate inflammatory cell infiltration in organs. These anti-inflammatory processes may result in an adaptive immune response and anti-SARS-CoV-2 antibody production. Interestingly, soluble epoxide hydrolase (sEH) produces EETs as metabolites. In some studies, SPMs and sEH inhibitors downregulate the expression of transcription regulator NF-κB and diminish the eicosanoid storms [10] .

There is an increase in the monocyte and macrophage levels in patients with COVID-19 [1] . Furthermore, epithelial cells, macrophages, and endothelial cells secrete cytokines in the lungs. The levels of IL-1, IL-2, IL-6, IL-7, IL-10, TNF-α, granulocyte colony-stimulating factor (GCSF), interferon-gamma-inducible protein 10, monocyte chemoattractant protein 1, and macrophage inflammatory protein 1-alpha are elevated in patients with COVID-19 [1, 11] (Fig. 3 ). Some of these cytokines are associated with lung injury in severe COVID-19 pneumonia. For example, an increased level of IL-6 is a poor prognostic factor in patients with COVID-19 and IL-10 is an anti-inflammatory cytokine that downregulates neutrophil and monocyte functions. Although IL-10 is beneficial for sepsis, the persistent downregulation of human leukocyte antigen-DR isotype (HLA-DR) by monocytes may lead to higher mortality. The cytokine storm results in the influx J o u r n a l P r e -p r o o f of various immune cells (macrophages, neutrophils, and T cells) from circulation to the lungs, thereby damaging endothelial cells, vascular barriers, capillaries, and alveoli, resulting in acute lung injury [1] . In patients with severe COVID-19, T lymphocytes produce less memory helper T cells and more naïve helper T cells [11] . With the occurrence of lymphocytopenia, the levels of subtypes of CD4 + and CD8 + T lymphocytes and NK cells decreases in patients with severe COVID-19. Despite the low level of lymphocytes in patients with severe COVID-19 and lymphocytopenia, the lymphocytes express high levels of HLA-DR and CD38.

According to the clinical characteristics of patients with COVID-19 pneumonia, comorbidities, such as COPD, are among the most important risk factors [12] .

Although the initial meta-analysis of Lippi et al. (2020) showed that smoking is not a proven risk factor of severe COVID-19, the authors only enrolled five study populations [13] . Alqahtani et al. studied both COPD and smoking status as risk factors for COVID-19 [14] . They analyzed 2,473 patients with COVID-19 and found that those with COPD have a higher risk of severe disease than those J o u r n a l P r e -p r o o f without COPD (relative risk (RR) = 1.88, 95% confidence interval: 1.4-2.4), whereas current smokers have more severe complications than former smokers and non-smokers (RR = 1.45, 95% CI: 1.03-2.04). Leung et al. [15] validated ACE2 expression in the Cornell (n = 211) and the British Columbia Cancer Agency (n = 238) cohorts and showed that ACE2 expression in current smokers is significantly higher than that in the controls. Jacobs et al. retrieved 134 subjects from lung tissue biobanks at Ghent University Hospital in Belgium [5] and reported that ACE2 mRNA expression is higher in current smokers than in nonsmokers. The authors also concluded that smoking status and COPD are associated with upregulated ACE2 mRNA expression independently, after adjusting for other factors. The same results were obtained in immunohistochemical (IHC) staining of ACE2 and analysis of protein levels in type II alveolar cells, bronchial epithelium, and alveolar tissue. One possible explanation is that smoking may upregulate the expression of the ACE2 receptor or that nicotine may influence the renin-angiotensin system and downregulate the expression of the ACE2 receptor (Fig. 1) . Additionally, ACE2 expression in patients with COPD is higher than that in patients with asthma, and it causes more severe COVID-19, as 961 patients were hospitalized [16] .

Interestingly, SARS-CoV cannot infect ACE2 knockout mice [17] . Moreover, the J o u r n a l P r e -p r o o f overexpression of human ACE2 in transgenic mouse models enhances the pathogenicity of SARS-CoV-2. This difference could be caused by the spike protein (S protein); although SARS-CoV and SARS-CoV-2 have similar structures, but SARS-Cov-2 S protein have higher occupancy (>90%) hydrogen bonds at S protein receptor-binding domain of ACE2 interface area. The mechanism indicates that SARS-Cov-2 can easily bind to ACE2 compared with SARS-CoV [18] .

Upon SARS-CoV-2 infection, the virus downregulates the expression of ACE2.

ACE2 is a negative regulator of the renin-angiotensin system that lowers the expression of Ang II. Decreased levels of ACE2, which is important for vasodilation, induce pneumonia and ARDS.

In China, cancer comorbidity is a risk factor for COVID-19, providing a poorer prognosis. In the Thoracic Cancers International COVID-19 Collaboration registry multicenter observational study, lung cancer was associated with high mortality and low ICU admission rate with COVID-19 infection [19] . Lung cancer patients with COVID-19 have high hospitalization, ARDS, and mortality rates.

COVID-19 is more severe in patients with lung cancer, smoking status, and [20, 21] Elective surgery is indicated for early-stage adenocarcinoma of the lung, such as stages I and II. An incidental finding of SARS-CoV-2 pneumonia after resection of lung cancer was reported by Tian et al. [22] . pandemic. In the UK Lung Cancer Coalition report, the proportion of patients with late-stage lung cancer has increased owing to possible overlapping symptoms with COVID-19 and the increasing stress on the respiratory healthcare services. 

Chest X-ray, especially in portable radiography, may be convenient and time saving for suspected pneumonia. However, it also increases the risk of contamination during portable chest radiographs. Conversely, chest radiographs correlated poorly with the clinical condition of COVID-19 compared with CT and ultrasound imaging [28] . CT data collected from patients with COVID-19 pneumonia showed bilateral patchy consolidation or ground-glass opacity, which may have a 10% crazypaving appearance [30] . The consolidation may have an air-bronchogram and the pleural effusion is usually absent. CT helps to identify COVID-19 pneumonia in the early phases. Ground-glass opacities were observed in the peripheral lung initially. Later, large consolidations were located over the basal or dependent part of the lung. The authors of the study also concluded that the maximum lung involvement peak was 10 days following the onset of initial symptoms and defined the disease stage using lung CT as stage 1: ground-glass opacities, stage 2: increased crazy-paving pattern, stage 3: consolidation, and stage 4: gradual resolution of consolidation without a crazy-paving pattern. The Dutch Association for Radiology created a standardized assessment of chest CT in COVID-19 pneumonia, the COVID-19 Reporting and Data System, with scores from 1 (highly unlikely) to 5 (highly likely) [20] . However, the specificity of CT remains low for differentiating COVID-19 in lung cancer patients [21] .

J o u r n a l P r e -p r o o f

There are pathological reports based on radiologic presentation [31] or autopsy [32, 33] . The gross appearance of an autopsy showed patchy peripheral hemorrhage of lung parenchyma [33] ; the alveoli lose their elasticity. On the cut surfaces, fibrous cords are found with sticky secretion exudate from the pulmonary alveoli, as well as the bronchus and trachea. By hematoxylin-eosin staining and IHC, diffuse alveolar damage, both alveolar exudative inflammation and interstitial inflammation, was found to be an ARDS [33] . Alveolar septa is where edematous, widened, congested, dilated blood vessels are present, and monocytes, lymphocytes, and macrophage infiltrate (interstitial mononuclear inflammatory infiltrates) the alveoli. Type II alveolar epithelial proliferation (hyperplasia) and focal desquamation of alveolar epithelia (denuded alveolar lining cells) were observed. Focal hemorrhage and occasional organization of exudates in alveolar cavities (intra-alveolar fibrinous exudates) and loose pulmonary interstitial fibrosis have been found. Hyaline membrane formation and partial bronchial epithelial exfoliation have also been found. Organizing pneumonia was diagnosed by intra-alveolar loose fibrous plugs and organizing fibrin. 

The lung is an important organ in humans; SARS-CoV-2 attacks the lungs via the The innate immune system includes macrophages, monocytes, dendritic cells, and neutrophils, which act through pattern recognition receptors (PRRs), detecting virusinduced pathogen-associated molecular patterns (PAMPs). PRRs included TLRs 3, 7, and 8, which can induce the production of cytokines such as IL-6, IL-10, and TNF-α.

Other PRRs, retinoic acid-inducible gene I (RIG-I) and melanoma differentiationassociated protein 5 (MDA5), could induce interferon response factor 3 (IRF3) or activation protein 1 (AP-1) producing type I IFNs (T1IFN) to inhibit infection.

Nucleotide-binding domain leucine-rich repeat (NLR) proteins also act as PRRs, which can detect endogenous danger-associated molecular patterns (DAMPs), activate inflammasomes, and covert pro-caspase-1 to AP-1, which then induces the conversion of pro-IL-1β to IL-1β. In adaptive immunity, SARS-CoV-2 induced CD4 + T cell differentiation to pathogenic Th1 cells, which produced IL-6 and granulocyte macrophage-colony-stimulating factor (GM-CSF) stimulating the recruitment of CD14 + CD16 + monocytes to the lungs. In addition, pro-inflammatory bioactive mediators such as eicosanoids, prostaglandins, and leukotrienes activate an J o u r n a l P r e -p r o o f inflammasome-induced eicosanoid storm. However, specialized pro-resolution mediators (SPMs) may mediate macrophage clearance of pro-inflammatory cytokine production, and soluble epoxide hydrolase (sEH) which could degrade arachidonic acid-derived epoxyeicosatrienoic acids (EETs) to inhibit inflammation. During infection, SARS-CoV-2 induces lung epithelial cells, endothelial cells, and macrophages to produce cytokines such as IL-1, IL-2, IL-6, IL-7, IL-10, TNF-α, granulocyte colony-stimulating factor (GCSF), interferon-gamma-inducible protein 10 (CXCL10), monocyte chemoattractant protein 1 (MCP-1), and macrophage inflammatory protein 1-alpha (MIP-1α). This causes a cytokine storm, leading to macrophage, monocyte, and neutrophil recruitment from circulation into the lungs inducing endothelial cell, vascular barrier, capillary, and alveolar damage, resulting in acute lung injury. SARS-CoV-2, through the renin-angiotensin-aldosterone system (RAAS), inhibits angiotensin-converting enzyme 2 (ACE2) convert angiotensin (Ang) II to Ang 1-7, resulting in higher Ang II levels in the plasma, and through AT1R binding to macrophages and monocytes, results in NF-κB-induced IL-1β, IL-6, IL-10, J o u r n a l P r e -p r o o f and TNF-α expression. Active AT1R through the MAPK-ERK1/2, JNK, and p38MPK pathways regulates IL-1, IL-10, IL-12, and TNF-α release, causing a cytokine storm.

In addition, SARS-CoV-2 causes lymphocytopenia, decreasing memory helper T, CD4 + and CD8 + lymphocytes, and NK cells.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

COVID-19 as the leading cause of death in the United States

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects

Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2

Importance of nucleic acid recognition in inflammation and autoimmunity

SARS and MERS: recent insights into emerging coronaviruses

Trilogy of ACE2: A peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters

Pro-resolving lipid mediators are leads for resolution physiology

Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19)

Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: A rapid systematic review and meta-analysis

ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19

Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Spike proteins of SARS-CoV and SARS-CoV-2 utilize different mechanisms to bind with human ACE2

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

CO-RADS: A categorical CT assessment scheme for patients suspected of having COVID-19-definition and evaluation

Screening for COVID-19 in symptomatic cancer patients in a cancer hospital

Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer

ESMO Management and treatment adapted recommendations in the COVID-19 era: lung cancer

Tocilizumab for COVID-19 pneumonia in a patient with non-small-cell lung cancer treated with chemoimmunotherapy

Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient

COVID-19 in lung transplant recipients: a multicenter study

When to consider lung transplantation for COVID-19

Chest radiographic and CT findings of the 2019 novel coronavirus disease (COVID-19): Analysis of nine patients treated in Korea

Our Italian experience using lung ultrasound for identification, grading and serial follow-up of severity of lung involvement for management of patients with COVID-19

Chest CT findings in coronavirus disease-19 (COVID-19): Relationship to duration of infection

2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: an uncommon radiological presentation

Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19

The pathological autopsy of coronavirus disease 2019 (COVID-2019) in China: a review

We would like to thank Editage (www.editage.com) for English language editing and publication support.J o u r n a l P r e -p r o o f